ASCO 2023 | SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma

Brian Van Tine, MD, PhD, Washington University, St. Louis, MO, provides an overview of overall survival findings from the Phase II SPEARHEAD-1 trial (NCT04044768) of afamitresgene autoleucel (afami-cel) in patients with HLA-A*02 and MAGE-A4 positive advanced synovial sarcoma. Patients were pretreated with lymphodepleting fludarabine and cyclophosphamide and overall survival was improved in patients receiving the CAR T-cell therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.